PTP4A2 and neoplasm: Mice treated with Cmpd-43 showed a significantly lower tumor burden, highlighting the efficacy of our PRL2 inhibitor to prevent tumorigenesis in this model (0.4189 g vs. 0.0929 g, P = 0.0020; Fig. 6B).